サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1787103

ライム病検査の世界市場

Lyme Disease Testing

出版日
ページ情報
英文 269 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
ライム病検査の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 269 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ライム病検査の世界市場は2030年までに186億米ドルに達する見込み

2024年に127億米ドルと推定されるライム病検査の世界市場は、2024年から2030年にかけてCAGR 6.6%で成長し、2030年には186億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるIGRA検査技術は、CAGR 5.4%を記録し、分析期間終了時には124億米ドルに達すると予測されます。その他の技術セグメントの成長率は、分析期間中CAGR 9.2%と推定されます。

米国市場は33億米ドルと推定、中国はCAGR6.5％で成長予測

米国のライム病検査市場は、2024年に33億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.5％を追いかけ、2030年までに30億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.9％と5.7％と予測されています。欧州では、ドイツがCAGR 5.4%で成長すると予測されています。

世界のライム病検査市場- 主要動向と促進要因のまとめ

なぜライム病検査が重要性を増しているのか？

ライム病はマダニが媒介する最も一般的な病気の一つであり、気候変動や流行地での野外活動の増加により症例が増加しています。ライム病を早期かつ正確に発見することは、神経や関節の問題など長期的な合併症を予防する上で非常に重要です。ダニ媒介性疾患に対する社会的認知が高まるにつれ、高度で信頼性の高いライム病検査への需要が高まっています。

技術革新はライム病検査の性能をどのように高めていますか？

分子診断学、血清学的アッセイ、迅速POC検査の進歩により、ライム病診断の精度とスピードが向上しています。次世代PCRベースの検査は、ボレリア菌を早期に検出することができ、従来の抗体検査に伴う偽陰性を減らすことができます。AIを活用した診断ツールや家庭用検査キットも登場し、より迅速で利用しやすい検査ソリューションを提供しています。さらに、研究者はライム病を他のダニ媒介性疾患と区別できるマルチターゲットアッセイを開発しています。

市場促進要因は？

ライム病の罹患率の上昇、公衆衛生への取り組みの増加、診断法の技術的進歩が市場促進要因です。政府機関や研究機関は、早期発見と治療成績向上のため、より優れた診断ツールに投資しています。屋外でのレクリエーション活動やペット飼育の増加傾向も、ライム病に対する認識と検査の必要性を高めています。

どのような課題と将来の機会が存在するか？

課題としては、検査精度のばらつき、高度な診断法の高コスト、地域によっては認知度が低いことなどが挙げられます。しかし、AIを用いたライム病検出ツールの開発、家庭用検査キットの普及、定期健康診断へのライム病スクリーニングの組み入れなど、チャンスは存在します。

セグメント

技術（IGRA検査技術、その他の技術）;検査（血清学的検査、リンパ球形質転換検査、尿中抗原検査、免疫蛍光染色検査、核酸検査）;サンプル（血液サンプル、尿サンプル、髄液サンプル、その他のサンプル）;エンドユーザー（病院エンドユーザー、診断ラボエンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Affymetrix, Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Ceres Nanosciences
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche AG
  • Galaxy Diagnostics
  • Gold Standard Diagnostics
  • Graphene Frontiers
  • IGeneX, Inc.
  • LabCorp
  • Meridian Bioscience, Inc.
  • Oxford Immunotec
  • Quest Diagnostics
  • Quidel Corporation
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech
  • ZEUS Scientific

AI統合

私たちは、検証された専門家のコンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP31942

Global Lyme Disease Testing Market to Reach US$18.6 Billion by 2030

The global market for Lyme Disease Testing estimated at US$12.7 Billion in the year 2024, is expected to reach US$18.6 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. IGRA Testing Technology, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$12.4 Billion by the end of the analysis period. Growth in the Other Technologies segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.3 Billion While China is Forecast to Grow at 6.5% CAGR

The Lyme Disease Testing market in the U.S. is estimated at US$3.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.9% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Lyme Disease Testing Market - Key Trends & Drivers Summarized

Why Is Lyme Disease Testing Gaining Importance?

Lyme disease is one of the most common tick-borne illnesses, with cases rising due to climate change and increased outdoor activities in endemic areas. Early and accurate detection of Lyme disease is critical to preventing long-term complications such as neurological and joint issues. As public awareness of tick-borne diseases grows, the demand for advanced and reliable Lyme disease testing is increasing.

How Are Innovations Enhancing the Performance of Lyme Disease Testing?

Advancements in molecular diagnostics, serological assays, and rapid point-of-care testing are improving the accuracy and speed of Lyme disease diagnosis. Next-generation PCR-based tests can detect the Borrelia bacteria at an early stage, reducing false negatives associated with traditional antibody tests. AI-driven diagnostic tools and at-home test kits are also emerging, providing faster and more accessible testing solutions. Additionally, researchers are developing multi-target assays that can distinguish Lyme disease from other tick-borne illnesses.

What Are the Key Market Drivers?

The rising incidence of Lyme disease, increased public health initiatives, and technological advancements in diagnostic methods are key market drivers. Government agencies and research institutions are investing in better diagnostic tools to enable early detection and improve treatment outcomes. The growing trend of outdoor recreational activities and pet ownership has also heightened the need for Lyme disease awareness and testing.

What Challenges and Future Opportunities Exist?

Challenges include the variability in test accuracy, high costs of advanced diagnostic methods, and limited awareness in some regions. However, opportunities exist in developing AI-assisted Lyme disease detection tools, expanding at-home test kit availability, and integrating Lyme disease screening into routine wellness check-ups.

SCOPE OF STUDY:

The report analyzes the Lyme Disease Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (IGRA Testing Technology, Other Technologies); Test (Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test, Nucleic Acid Test); Sample (Blood Sample, Urine Sample, CSF Sample, Other Samples); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Abbott Laboratories
  • Affymetrix, Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Ceres Nanosciences
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche AG
  • Galaxy Diagnostics
  • Gold Standard Diagnostics
  • Graphene Frontiers
  • IGeneX, Inc.
  • LabCorp
  • Meridian Bioscience, Inc.
  • Oxford Immunotec
  • Quest Diagnostics
  • Quidel Corporation
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech
  • ZEUS Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Lyme Disease Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Lyme Disease Throws the Spotlight on Early and Accurate Diagnostic Solutions
    • Increased Awareness of Tick-Borne Illnesses Spurs Demand for Preventive Testing and Screening Services
    • Expansion of Point-of-Care Testing Capabilities Enhances Accessibility in Rural and Underserved Areas
    • Advancements in Molecular and Serological Testing Methods Strengthen Diagnostic Accuracy and Speed
    • Growing Availability of At-Home Lyme Disease Test Kits Expands Direct-to-Consumer Market Opportunity
    • Government and NGO-Funded Public Health Campaigns Propel Testing Awareness and Uptake
    • Integration of Lyme Testing Into Routine Travel and Outdoor Health Checkups Increases Market Penetration
    • Increase in Outdoor Recreational Activities Post-Pandemic Drives Risk-Based Testing Demand
    • Regulatory Push for Standardization and Test Validation Improves Reliability Across Commercial Test Providers
    • Rising Clinical Interest in Co-Infections and Chronic Lyme Disease Supports Multi-Pathogen Testing Platforms
    • Insurance Coverage Expansion in North America Enhances Affordability and Uptake of Lyme Testing
    • Growth in Personalized and Preventive Medicine Accelerates Demand for Early Diagnostic Tools
    • Growing Concerns Over Misdiagnosis and Delayed Treatment Strengthen Business Case for Improved Test Accuracy
    • Adoption of AI and Predictive Analytics in Lab Testing Enhances Efficiency in Diagnosis and Reporting
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Lyme Disease Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Lyme Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Lyme Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Lyme Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for IGRA Testing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for IGRA Testing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for IGRA Testing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for CSF Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for CSF Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for CSF Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Samples by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Blood Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Serological Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Serological Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Serological Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Lymphocytic Transformation Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Lymphocytic Transformation Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Lymphocytic Transformation Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Urine Antigen Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Urine Antigen Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Urine Antigen Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Immunofluorescent Staining Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Immunofluorescent Staining Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Immunofluorescent Staining Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Nucleic Acid Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Nucleic Acid Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Nucleic Acid Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • JAPAN
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • CHINA
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • EUROPE
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Lyme Disease Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Lyme Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • FRANCE
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • GERMANY
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Lyme Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 182: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of World Historic Review for Lyme Disease Testing by Technology - IGRA Testing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of World 15-Year Perspective for Lyme Disease Testing by Technology - Percentage Breakdown of Value Sales for IGRA Testing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of World Historic Review for Lyme Disease Testing by Sample - CSF Sample, Other Samples, Blood Sample and Urine Sample Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of World 15-Year Perspective for Lyme Disease Testing by Sample - Percentage Breakdown of Value Sales for CSF Sample, Other Samples, Blood Sample and Urine Sample for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of World Historic Review for Lyme Disease Testing by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of World 15-Year Perspective for Lyme Disease Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of World Recent Past, Current & Future Analysis for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of World Historic Review for Lyme Disease Testing by Test - Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of World 15-Year Perspective for Lyme Disease Testing by Test - Percentage Breakdown of Value Sales for Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test and Nucleic Acid Test for the Years 2015, 2025 & 2030

IV. COMPETITION